Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT253
- Development stage
- Unknown
- Lead developer
- Guangdong Celconta Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CT253 (also known as XKDCT253) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Guangdong Celconta Biotechnology. It utilizes the company's proprietary Boost-CAR platform to target Claudin 18.2 (CLDN18.2), a protein frequently overexpressed in various solid tumors, particularly gastric and gastroesophageal junction cancers. The Boost-CAR technology is designed to enhance the expansion and persistence of CAR-T cells in the immunosuppressive tumor microenvironment. CT253 is currently being evaluated in clinical trials for the treatment of CLDN18.2-positive advanced solid malignant tumors, including gastric, esophageal, and gastroesophageal junction cancers.
- Other names
- XKDCT253 Cell PreparationXKDCT-253 Cell PreparationXKDCT 253 Cell Preparation
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on CT253.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT253.